Form 4: Fulgent Genetics COO Sells Shares for Tax Obligations

Fulgent Genetics President and COO, Xie Jian, sold 1,128 shares of common stock to satisfy tax obligations related to vested restricted stock units.

Summary

• Xie Jian, President and COO of Fulgent Genetics, Inc. (FLGT), reported a transaction on September 3, 2025.
• The transaction involved the sale of 1,128 shares of Fulgent Genetics common stock.
• The shares were sold at a weighted-average price of $22.0267 per share, with individual transaction prices ranging from $21.92 to $22.175.
• The purpose of the sale was to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs) granted on February 28, 2022.
• Following the transaction, Xie Jian directly beneficially owns 364,121 shares of common stock.
• Additionally, 220,816 shares are indirectly beneficially owned by The Hsieh Family Dynasty Trust, where Mr. Xie serves on the investment committee.

Sentiment

Score: 5

Explanation: The transaction is a routine sale to cover tax obligations from vested restricted stock units, not indicative of management's view on the company's future prospects or a significant change in beneficial ownership.

Industry Context

This filing details a routine insider transaction related to equity compensation, which is a common practice across various industries for executives receiving restricted stock units. It does not provide specific insights into broader industry trends or competitive landscape.

Related Party Transactions

• The Hsieh Family Dynasty Trust, dated January 27, 2010, indirectly holds 220,816 shares, and Mr. Xie serves on its investment committee. Mr. Xie disclaims beneficial interest except for any pecuniary interest.

Stakeholder Impact

• Shareholders: The sale of 1,128 shares by a key executive is a routine, tax-related event and represents a very small fraction of the company's outstanding shares and the executive's total holdings, thus having minimal direct impact on the broader shareholder base or share price.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this insider transaction filing.

Key Dates

Recommendation

The filing details a routine insider sale of a small number of shares to cover tax obligations upon the vesting of restricted stock units. This type of transaction is not indicative of a change in the company's fundamentals or management's long-term outlook, and therefore does not warrant a change in investment posture based solely on this filing.

Keywords

Fulgent Genetics, FLGT, Xie Jian, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, Corporate Officer